close

Agreements

Date: 2012-04-17

Type of information: Development agreement

Compound: recombinant interferon product

Company: Angel Biotechnology (UK) TransGenRx (USA)

Therapeutic area:

Type agreement:

development

Action mechanism:

Disease:

Details:

The biopharmaceutical contract manufacturer Angel Biotechnology has agreed a contract with TransGenRx for the development and scale up of a recombinant interferon product. The purpose of the contract is to attain acceptable expression levels on which to establish a GMP manufacturing process, which would then be conducted by Angel.

Financial terms:

This development work for TransGenRx will take place at Angel\'s GMP facility at Cramlington and will have a value in excess of £800,000 ($1.3 million).

Latest news:

Is general: Yes